
This review presents a therapeutic nanowafer as an alternative to eye drops for dry eye disease, designed to enhance efficacy and improve patient compliance to treatment. In an experimental animal study, the novel dexamethasone nanowafer drug delivery system was comparable in efficacy to twice-daily dexamethasone eye drop treatment and has the potential to minimise risk of cataract formation and glaucoma.
